Drugs / PANDA-VAC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04266730 | May → Jun 2027 | head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PANDA-VAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04266730 ↗ |
| Modality | Vaccine | “personalized and adjusted neoantigen peptide vaccine (PANDA-VAC)” NCT04266730 ↗ |
| Route | Subcutaneous | “PANDA-VAC will be administered subcutaneously” NCT04266730 ↗ |